{"id":"comparator-truvada","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Rash"},{"rate":"2-5","effect":"Renal impairment (with long-term use)"},{"rate":"variable","effect":"Bone density loss"}]},"_chembl":{"chemblId":"CHEMBL3983509","moleculeType":"Small molecule","molecularWeight":"434.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Truvada contains emtricitabine and tenofovir disoproxil fumarate, which are nucleoside analogs that inhibit HIV reverse transcriptase, an enzyme essential for converting HIV RNA into DNA. By blocking this enzyme, the drug prevents HIV from integrating into host cell DNA and establishing infection. It is used both as antiretroviral therapy for HIV-positive individuals and as pre-exposure prophylaxis (PrEP) in HIV-negative individuals at high risk.","oneSentence":"Truvada is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that blocks HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:19.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection treatment in combination with other antiretroviral agents"},{"name":"Pre-exposure prophylaxis (PrEP) for HIV-1 prevention in high-risk individuals"}]},"trialDetails":[{"nctId":"NCT04405271","phase":"PHASE3","title":"TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)","status":"TERMINATED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2020-07-31","conditions":"Healthcare Workers, COVID-19, SARS-CoV 2","enrollment":1378},{"nctId":"NCT06656676","phase":"NA","title":"WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-01-29","conditions":"HIV Prevention","enrollment":75},{"nctId":"NCT02403674","phase":"PHASE3","title":"Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":734},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT05663892","phase":"PHASE4","title":"Drug-Drug Interaction Study in Trans Women Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maple Leaf Research","startDate":"2022-11-23","conditions":"Hiv, Transgenderism","enrollment":45},{"nctId":"NCT04549467","phase":"PHASE4","title":"Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test","status":"COMPLETED","sponsor":"Fundacion IDEAA","startDate":"2020-11-17","conditions":"Hiv, HIV-1-infection","enrollment":244},{"nctId":"NCT02131233","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"HIV Infection","enrollment":802},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT00369941","phase":"PHASE3","title":"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"HIV Infections","enrollment":566},{"nctId":"NCT00745823","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"HIV","enrollment":775},{"nctId":"NCT01343225","phase":"PHASE4","title":"Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2011-05","conditions":"HIV","enrollment":40},{"nctId":"NCT00244712","phase":"PHASE4","title":"Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"HIV Infection","enrollment":688},{"nctId":"NCT00323492","phase":"PHASE4","title":"TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-09","conditions":"HIV Infections","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["emtricitabine/tenofovir disoproxil fumarate"],"phase":"phase_3","status":"active","brandName":"Comparator: Truvada","genericName":"Comparator: Truvada","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Truvada is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection treatment in combination with other antiretroviral agents, Pre-exposure prophylaxis (PrEP) for HIV-1 prevention in high-risk individuals.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}